Drugs / Sennosides
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03475680 | Aug 2018 → Aug 2021 | colon carcinoma | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01531140 | Nov 2010 → Nov 2011 | — | Medical University of Warsaw | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT00001337 Background | May 1993 → May 2024 | Burkitt lymphoma, anaplastic large cell lymphoma, mediastinal gray zone lymphoma, primary mediastinal large B-cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT06561035 Background | Sep 2024 → Dec 2027 expected | — | Campbell Clinic | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT03491540 Background | Sep 2018 → Oct 2023 | rectal cancer | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT02618564 Comparator | Jan 2016 → Aug 2017 | — | Queen's University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sennosides | “8. Senokot-S (Sennosides and Docusate) as needed for constipation.” NCT06561035 ↗ |
| Known as | Sennosides: Xenna | “Sennosides: Xenna” NCT01531140 ↗ |
| Known as | X-PREP | “Sennosides colonic preparation (X-PREP)” NCT03475680 ↗1“Sennosides colonic preparation (X-PREP)” NCT03491540 ↗ |